InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

Current share price for CUV : $8.260 0.1 (1.20%)+

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$417 Ceasing to be a substantial holder 2 Sep 2026 8:15AM $8.240 $8.260 risen by 0.24%
$417 CLINUVEL considers Nasdaq listing, ASX delisting 27 Aug 2026 12:33PM $10.690 $8.260 fallen by 22.73%
$417 Investor Presentation 27 Aug 2026 12:28PM $10.690 $8.260 fallen by 22.73%
$417 Appendix 4G 27 Aug 2026 12:26PM $10.690 $8.260 fallen by 22.73%
$417 Corporate Governance Statement 27 Aug 2026 12:25PM $10.690 $8.260 fallen by 22.73%
$417 Dividend/Distribution - CUV 27 Aug 2026 12:24PM $10.690 $8.260 fallen by 22.73%
$417 A decade of profitability provides U.S. expansion foundation 27 Aug 2026 12:22PM $10.690 $8.260 fallen by 22.73%
$417 Appendix 4E and Annual Report to Shareholders 2026 27 Aug 2026 12:21PM $10.690 $8.260 fallen by 22.73%
$417 CLINUVEL Annual Results - Investor Webinar 20 Aug 2026 9:07AM $10.400 $8.260 fallen by 20.58%
$417 Becoming a substantial holder 14 Aug 2026 8:16AM $9.590 $8.260 fallen by 13.87%
$417 CLINUVEL's injectable peptide platform 12 Aug 2026 9:12AM $9.710 $8.260 fallen by 14.93%
$417 Commercial update on vitiligo 30 Jul 2026 8:57AM $9.590 $8.260 fallen by 13.87%
$417 Update - SCENESSE in vitiligo 28 Jul 2026 8:56AM $9.810 $8.260 fallen by 15.80%
$417 Notification of cessation of securities - CUV 27 Jul 2026 8:48AM $10.060 $8.260 fallen by 17.89%
$417 CLINUVEL strategic reorganisation to refocus on U.S. markets 23 Jul 2026 9:11AM $9.880 $8.260 fallen by 16.40%
$417 CLINUVEL's ADS commences trading on Nasdaq 21 Jul 2026 8:35AM $10.240 $8.260 fallen by 19.34%
$417 CLINUVEL's ADS to commence trading on Nasdaq 20 Jul 2026 8:33AM $9.920 $8.260 fallen by 16.73%
$417 SCENESSE approved for EPP in Canada 13 Jul 2026 8:34AM $10.270 $8.260 fallen by 19.57%
$417 CLINUVEL confirms terms of CEO's Employment Agreement 2 Jul 2026 11:36AM $10.350 $8.260 fallen by 20.19%
$417 CLINUVEL publicly files 20-F to U.S. SEC 16 Jun 2026 9:06AM $9.250 $8.260 fallen by 10.70%
$417 CLINUVEL US Non-Deal Roadshow Presentation 2 Jun 2026 9:26AM $9.260 $8.260 fallen by 10.80%
$417 Notification regarding unquoted securities - CUV 7 May 2026 11:45AM $9.490 $8.260 fallen by 12.96%
$417 CLINUVEL update on Level II ADR upgrade, Nasdaq uplist 28 Apr 2026 8:50AM $8.980 $8.260 fallen by 8.02%
$417 FDA relaxes SCENESSE postmarketing requirement 27 Apr 2026 8:42AM $9.040 $8.260 fallen by 8.63%
$417 Final EMA scientific advice for pivotal Phase III vitiligo 24 Apr 2026 8:56AM $8.810 $8.260 fallen by 6.24%

1 - 25 of 870 results

Page 1 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.